Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

Transgene and NEC will present promising new data from the ongoing randomized Phase I trial of the neoantigen individualized therapeutic cancer vaccine, TG4050 at SITC 2024 on November 9, 2024 (see ...

Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Vaccibody, which is also entitled to tiered royalties on sales of any marketed products, will develop the DNA-based individualised neoantigen vaccines until the end of phase 1b. Genentech ...

The findings were published Oct. 16 in Nature in a paper titled "Probiotic neoantigen delivery vectors for precision cancer immunotherapy." The bacterial vaccine proved to be particularly more ...

PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free ...

to design personalized cancer vaccines has been developed by scientists at Ludwig Cancer Research (1 Trusted Source A comprehensive proteogenomic pipeline for neoantigen discovery to ...

Dr. Emmanuelle Dochy, chief medical officer of Transgene, added: "We are very encouraged to observe that all the patients treated with our neoantigen cancer vaccine TG4050 remain disease-free after a ...